Compare GIPR & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIPR | INDP |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 5.2M |
| IPO Year | N/A | 2021 |
| Metric | GIPR | INDP |
|---|---|---|
| Price | $0.17 | $3.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 950.0K | ★ 2.6M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.92 |
| 52 Week High | $1.99 | $13.24 |
| Indicator | GIPR | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 50.20 |
| Support Level | $0.16 | $2.43 |
| Resistance Level | $0.28 | $3.24 |
| Average True Range (ATR) | 0.02 | 0.56 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 36.05 | 10.33 |
Generation Income Properties Inc is an internally managed real estate investment trust focused on acquiring and managing income-producing retail, office, and industrial properties net leased to high-quality tenants in different states throughout the United States. Its key source of revenue is the rental income. The trust's properties are generally net leased to a single tenant.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.